Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) $ / shares in Units, $ in Millions						3 Months Ended		6 Months Ended
	Oct. 25, 2022 USD ($) $ / shares shares	Oct. 20, 2022 USD ($)	Jun. 27, 2022	Jun. 24, 2022	Aug. 11, 2020 USD ($) $ / shares	Jun. 30, 2023 $ / shares shares	Mar. 31, 2023 shares	Jun. 30, 2023 $ / shares shares	Dec. 31, 2022 $ / shares
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares						8,235,189		8,235,189
Common stock par value \| $ / shares						$ 0.00001		$ 0.00001	$ 0.00001
Stockholders' Equity Note, Stock Split, Conversion Ratio			0.10
Sales Agent \| Equity Distribution Agreement
STOCKHOLDERS' EQUITY
Aggregate value of shares issued \| $					$ 14.5
Common stock par value \| $ / shares					$ 0.00001
Commission paid on sale of shares (in percentage)					3.00%
Common Stock
STOCKHOLDERS' EQUITY
Conversion of pre-funded warrants into common shares (in shares)							355,235
Minimum
STOCKHOLDERS' EQUITY
Stockholders' Equity Note, Stock Split, Conversion Ratio				0.10
Maximum
STOCKHOLDERS' EQUITY
Stockholders' Equity Note, Stock Split, Conversion Ratio				0.20
October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares	3,275,153
Exercise price of warrants (in dollars per share) \| $ / shares	$ 2.085
class of warrant or rights from which warrants or rights exercisable. \| $ / shares	$ 0.00001
proceeds from issuance of private placement \| $	$ 10.7
Estimated offering expenses \| $	$ 9.6
Gross proceeds from stockholders' equity \| $		$ 10.7
October 2022 Public Offering and Private Placement \| Common Stock
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares	1,875,945
Exercise price of warrants (in dollars per share) \| $ / shares	$ 1.96
Common Stock \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Conversion of pre-funded warrants into common shares (in shares)								355,235
Gross proceeds from stockholders' equity \| $		4.0
Common warrants \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Gross proceeds from stockholders' equity \| $		4.4
Prefunded Warrant \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares	1,875,945
Exercise price of warrants (in dollars per share) \| $ / shares	$ 2.08499
pre-funded warrants								355,235
Number of warrants exercised						0
Gross proceeds from stockholders' equity \| $		$ 2.3